About Us

Company Overview

Cardiol Therapeutics is a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease

The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific and Business Advisory Boards comprising business and thought leaders with extensive industry experience and expertise in commercializing proprietary drugs. Learn more…

Cardiol has received approval from the U.S. FDA for its Investigational New Drug (IND) application to commence a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead clinical product, CardiolRx™, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). Learn more…CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC free*. Learn more…

Cardiol is also planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age, Learn more… and developing proprietary cannabidiol formulations for the treatment of chronic heart failure. Chronic heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion. Learn more…

The Company has research collaborations focused on developing a subcutaneous cannabidiol formulation for heart failure underway at international centers of excellence, including the Houston Methodist DeBakey Heart & Vascular Center, the University of Alberta, and TecSalud del Tecnológico de Monterrey, Mexico. Learn more…

*<10 ppm